MRI Scans Underutilized in U.S. Prostate Cancer Diagnosis Despite Global Standard

While pre-biopsy MRI has become the standard diagnostic approach for prostate cancer in most Western countries, recent data reveals that only about one-third of U.S. prostate cancer cases involved MRI imaging in 2022. This significant gap in diagnostic practices highlights a disparity between American healthcare standards and international protocols. MRI scans help identify suspicious lesions and guide biopsies more accurately, potentially reducing unnecessary procedures and improving patient outcomes. The underutilization of this technology in the U.S. raises questions about accessibility, cost, awareness among physicians, and insurance coverage barriers that may be preventing more widespread adoption of this evidence-based diagnostic standard.